Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia
2017; Elsevier BV; Volume: 131; Issue: 8 Linguagem: Inglês
10.1182/blood-2017-08-797886
ISSN1528-0020
AutoresChristine Chen, David S. Siegel, Martin Gutierrez, Meagan A. Jacoby, Craig C. Hofmeister, Nashat Gabrail, Rachid Baz, Morten Mau‐Sørensen, Jesús G. Berdeja, Michael R. Savona, Lynn Savoie, Suzanne Trudel, Nuchanan Areethamsirikul, Thaddeus J. Unger, Tami Rashal, Tim Hanke, Michael Kauffman, Sharon Shacham, Donna Reece,
Tópico(s)Ubiquitin and proteasome pathways
ResumoKey Points Selinexor is an oral XPO1 inhibitor with antimyeloma activity. The RP2D is 45 mg/m2 (80 mg) selinexor plus 20 mg dexamethasone given twice weekly.
Referência(s)